Literature DB >> 12036867

Induction of T-cell tolerance to an MHC class I alloantigen by gene therapy.

Jessamyn Bagley1, Chaorui Tian, David H Sachs, John Iacomini.   

Abstract

Induction of immunologic tolerance to alloantigens is a major goal in the field of transplantation. Here, we demonstrate that efficient transduction and expression of a retrovirally transduced major histocompatibility complex (MHC) class I gene (H-2K(b)) in bone marrow (BM)-derived cells, resulting in a permanent state of hematopoietic molecular chimerism, induces stable tolerance to the transduced gene product. Reconstitution of lethally irradiated syngeneic recipients with BM transduced with virus encoding H-2K(b) resulted in life-long expression of the retroviral gene product on the surface of BM-derived hematopoietic lineages including Sca-1(+), lineage negative, hematopoietic progenitors. T cells from mice receiving MHC-transduced BM were unable to kill targets expressing H-2K(b) but were able to respond to third-party controls. Mice reconstituted with H-2K(b)-transduced BM exhibited long-term acceptance of H-2K(b) mismatched skin grafts but were able to rapidly reject third-party control grafts. Thus, gene therapy approaches may be used to induce T-cell tolerance.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12036867     DOI: 10.1182/blood.v99.12.4394

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

1.  Induction of transplantation tolerance to fully mismatched cardiac allografts by T cell mediated delivery of alloantigen.

Authors:  Chaorui Tian; Xueli Yuan; Peter T Jindra; Jessamyn Bagley; Mohamed H Sayegh; John Iacomini
Journal:  Clin Immunol       Date:  2010-05-08       Impact factor: 3.969

2.  Past, present, and future prospects for inducing donor-specific transplantation tolerance for composite tissue allotransplantation.

Authors:  Larry D Bozulic; Warren C Breidenbach; Suzanne T Ildstad
Journal:  Semin Plast Surg       Date:  2007-11       Impact factor: 2.314

3.  Tolerization of a type I allergic immune response through transplantation of genetically modified hematopoietic stem cells.

Authors:  Ulrike Baranyi; Birgit Linhart; Nina Pilat; Martina Gattringer; Jessamyn Bagley; Ferdinand Muehlbacher; John Iacomini; Rudolf Valenta; Thomas Wekerle
Journal:  J Immunol       Date:  2008-06-15       Impact factor: 5.422

4.  Tackling autoimmunity with gene therapy.

Authors:  Frank Alderuccio; Ban-Hock Toh
Journal:  Chimerism       Date:  2012-07-01

5.  Advancements in gene transfer-based therapy for hemophilia A.

Authors:  Christopher B Doering; H Trent Spencer
Journal:  Expert Rev Hematol       Date:  2009-12       Impact factor: 2.929

6.  Engineered Hematopoietic Stem Cells as Therapeutics for Hemophilia A.

Authors:  Philip M Zakas; H Trent Spencer; Christopher B Doering
Journal:  J Genet Syndr Gene Ther       Date:  2011-11-16

7.  Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer.

Authors:  Federico Mingozzi; Yi-Lin Liu; Eric Dobrzynski; Antje Kaufhold; Jian Hua Liu; YuQin Wang; Valder R Arruda; Katherine A High; Roland W Herzog
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

8.  Tolerance induction in experimental autoimmune encephalomyelitis using non-myeloablative hematopoietic gene therapy with autoantigen.

Authors:  Herena Eixarch; Carmen Espejo; Alba Gómez; María José Mansilla; Mireia Castillo; Alexander Mildner; Francisco Vidal; Ramón Gimeno; Marco Prinz; Xavier Montalban; Jordi Barquinero
Journal:  Mol Ther       Date:  2009-03-10       Impact factor: 11.454

9.  Transgene expression levels determine the immunogenicity of transduced hematopoietic grafts in partially myeloablated mice.

Authors:  Herena Eixarch; Alba Gómez; Elisabeth Kádár; Mónica George; Nuria Martínez; Carmen Espejo; Jordi Pétriz; Ramon Gimeno; Jordi Barquinero
Journal:  Mol Ther       Date:  2009-08-25       Impact factor: 11.454

10.  Persistent molecular microchimerism induces long-term tolerance towards a clinically relevant respiratory allergen.

Authors:  U Baranyi; N Pilat; M Gattringer; B Linhart; C Klaus; E Schwaiger; J Iacomini; R Valenta; T Wekerle
Journal:  Clin Exp Allergy       Date:  2012-08       Impact factor: 5.018

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.